secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001140361-23-014819
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Biosciences amends business combination agreement, extends outside date to Sept 30, 2023
--------------------------------------------------------------------------------

- Extended outside date for business combination with GNI Group to September 30, 2023.
- Operating company options to be replaced with options under Parent's 2023 Omnibus Incentive Plan.
- Contributors to reimburse Catalyst for operating expenses over $500k up to $1M, and all expenses from July 20, 2023 to closing.
- Amended F351 asset purchase agreement extends deadline for cash settlement of conversion shares to September 30, 2023.
- Amended Contingent Value Rights Agreement to reflect sale of certain assets under GCB APA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/0001140361-23-014819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123014819/brhc10050607_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-014819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer